Is Phibro Animal Health Corp. overvalued or undervalued?

As of 28 August 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be fairly valued given its current metrics, particularly with a P/E ratio of 21, a Price to Book Value of 3.67, and an EV to EBITDA of 9.97. In comparison to peers, Phibro's P/E ratio is significantly lower than Soleno Therapeutics, Inc. at -21.86, suggesting a more favorable valuation despite the industry challenges.
Phibro has shown strong performance with a year-to-date return of 93.05%, significantly outperforming the S&P 500's 12.22% during the same period. However, over the longer term, its 10-year return of 125.72% lags behind the S&P 500's 231.64%, highlighting potential areas for improvement. Overall, while the company is currently fairly valued, its strong returns indicate robust market confidence.